Phase II study of gemcitabine, UFT and leucovorin in patients with advanced pancreatic cancer

9Citations
Citations of this article
6Readers
Mendeley users who have this article in their library.

Abstract

The combination of gemcitabine with protracted 5-fluorouracil(5-FU) in the treatment of metastatic pancreatic cancer has shown activity with tolerable toxicity. The administration of UFT may simulate the effects of a protracted infusion of 5-FU. Patients with previously untreated metastatic or unresectable measurable pancreatic adenocarcinoma received gemcitabine (800 mg/m2 i.v., administered as an 80-min infusion on days 1, 8 and 15), UFT (200 mg/m2/day, on days 1 to 21), and oral leucovorin (90 mg/day, on days 1 to 21). Thirty patients were enrolled in this study. Five patients had partial responses, with an overall response rate of 17% (5/30), using the intent-to-treat principle (95% confidence interval (CI), 3-30%). Nine out of 25 (36%) patients experienced clinical benefit responses (95% CI; 17-55%). The median time to progression was 3.0 months, and the median overall survival was 7.2 months. The principal adverse event was neutropenia. The combination of gemcitabine, UFT, plus oral leucovorin shows significant antitumor activity and a beneficial clinical effect with an acceptable level of toxicity.

Cite

CITATION STYLE

APA

Kim, T. W., Kang, H. J., Ahn, J. H., Lee, K., Chang, H. M., Kang, Y. K., & Lee, J. S. (2002). Phase II study of gemcitabine, UFT and leucovorin in patients with advanced pancreatic cancer. Acta Oncologica, 41(7–8), 689–694. https://doi.org/10.1080/028418602321028328

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free